T-NHL-2009方案治疗儿童淋巴母细胞性淋巴瘤预后及不良反应

Prognosis and side effects of T-HNL-2009 protocol on treatment of lymphoblastic lymphoma in children

目的探讨T-NHL-2009方案治疗儿童淋巴母细胞性淋巴瘤(LBL)的疗效和安全性。方法收集并分析23例确诊为LBL并接受TNH-2009方案治疗的患儿临床资料、疗效及不良反应。结果 23例患儿中5例为B-LBL,17例为T-LBL;1个疗程后17例达到完全缓解(CR),CR百分率为73.91%。CR患儿中复发1例,3年预期无事件生存率为89.87%;患儿无治疗相关病死,化疗不良反应以Ⅲ度以上骨髓抑制、感染和肝损伤最常见。诱导Ⅱ方案肝损伤发生率最高。结论使用不含颅脑放疗的T-NHL-2009方案治疗儿童LBL安全有效。

Objective To retrospectively analyze the prognosis and efficacy of T-NHL-2009 protol on lymphoblastic lymphoma （LBL） in children. Methods Clinical data,prognosis and side effects of 23 children who were confirmed with LBL were collected and analyzed. Results 23 children which included 5 cases of B-LBL and 17 cases of T-LBL were involved in the study;17 children achieved complete remission after 1 course of chemotherapy,the CR rate was 73.91%. In the 17 cases who achieved CR, 1 case relapsed and prospective event free survival rate was 89.87%;there was no death due to therapy, common side effects by chemothera- py includes Ⅲ and Ⅳ degree myelosuppression,infection and hepatic insufficiency,incidence of hepatic insufficiency was dominant during course of induction Ⅱ. Conclusion Protocol of TNHL-2009 without cranial radiotherapy is effective and efficacy for children who suffered from LBL.